These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32108461)

  • 1. Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
    Tonacci A; Nettis E; Asero R; Rossi O; Tontini C; Gangemi S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(3):100-103. PubMed ID: 32108461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
    Farrah G; Stevenson B; Lie K; Brusch A
    Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 4. Age and fast initial response predict omalizumab retreatment in chronic urticaria.
    Meertens MAJ; Luijf T; van Lindonk EAM; Soegiharto R; Assil S; Alizadeh Aghdam M; Kentie PA; Knulst AC; van Doorn MBA; Röckmann H
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3556-3558.e1. PubMed ID: 37517795
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
    Dortas Junior S; Azizi G; Valle S
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
    [No Abstract]   [Full Text] [Related]  

  • 6. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
    Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
    [No Abstract]   [Full Text] [Related]  

  • 7. Omalizumab re-treatment rates in chronic spontaneous urticaria.
    Khan S; Sholtysek S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397
    [No Abstract]   [Full Text] [Related]  

  • 8. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
    Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
    Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
    Cho YT; Fu KT; Yang CW; Chu CY
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
    Di Leo E; Calogiuri G; Macchia L; Nettis E
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
    Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
    Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Belbezier A; Boccon-Gibod I; Bouillet L
    Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Hayama K; Fujita H; Asai-Sato M; Kawana K; Terui T
    Eur J Dermatol; 2021 Feb; 31(1):100-101. PubMed ID: 33459258
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
    Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
    Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
    Ayhan E; Öztürk M; An İ; Bekçİbaşi M
    Int J Dermatol; 2021 Feb; 60(2):253-254. PubMed ID: 33332576
    [No Abstract]   [Full Text] [Related]  

  • 17. Omalizumab for chronic urticaria in children younger than 12 years.
    Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
    Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
    Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
    J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.